SMARCA4 and lung cancer: In the case of BRG1 deficiency in lung cancer cells, these cells were shown to be sensitive to ATR inhibitors, which may provide a therapeutic strategy for targeting tumors deficient in the BRD protein BRG1 or other potential loss-of-function mutations that may be present in other SWI/SNF protein complex members53,61.